* BELLICUM PHARMACEUTICALS PROVIDES OPERATIONAL UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017
* REMAINS ON TRACK TO FILE EUROPEAN MARKETING AUTHORIZATION APPLICATIONS FOR BPX-501 AND RIMIDUCID IN 2019
* Q4 EARNINGS PER SHARE VIEW $-0.70 — THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)